Lambda Biologics will be exhibiting at AACR 2026, one of the world’s leading conferences dedicated to advancing cancer research, where we will present our latest advancements in oncology-focused organoid platforms designed to generate more predictive, human-relevant translational insights.
- 17–22 April 2026
- San Diego Convention Center
TME Interplay with Organoids
Cancer progression is not driven by tumor cells alone. The dynamic interplay between tumor cells, immune components, extracellular matrix (ECM), and stromal cells critically shapes therapeutic response.
Lambda Biologics’ oncology solutions are designed to:
- Reconstruct patient-relevant tumor microenvironments in vitro
- Enable real-time observation of tumor growth and immune–tumor interactions
- Model ECM and stromal influences on tumor behavior
- Support mechanistic studies of cancer development
- Evaluate drug response and immune modulation in a physiologically relevant setting
Our integrated tumor organoid – TME platforms help bridge the gap between simplified in vitro systems and complex patient biology.
Introducing Our New Solution at AACR 2026
At AACR 2026, we will introduce a newly developed quantitative MDSC infiltration assay built within a tumor organoid–stromal microenvironment.
Designed for immuno-oncology research, this platform enables quantitative assessment of immune cell trafficking and immunosuppressive activity in a structured, human-relevant TME context – supporting more mechanism-informed candidate evaluation.
More details will be shared at the event.
If you are working on tumor microenvironment modeling, immuno-oncology, or translational oncology research, we would be delighted to connect.
- Visit us at Booth 1603
- Book a meeting in advance to explore collaboration opportunities
Lambda Biologics’ Oncology Solutions: Patient-derived cancer organoid-based drug evaluation service
Gastric Cancer Organoid | Breast Cancer Organoid | Hepatocarcinoma Cancer Organoid | Pancreatic Cancer Organoid
